Abstract
Summary Background The treatment of pemphigus is still challenging and some patients with pemphigus are unresponsive to conventional immunosuppressive treatments. Rituximab, a chimeric monoclonal anti-CD20 antibody, binds to the CD20 antigen on the surface of B cells and has been reported to be effective for the treatment of recalcitrant pemphigus. Objective To compare the efficacy of different doses of rituximab in patients with pemphigus who were unresponsive to conventional therapies. Methods Twenty-seven patients with pemphigus who received different doses of rituximab (375 mg m -2 per infusion weekly) were analysed retrospectively. We divided the patients into two groups: group 1 (n = 12) received two infusions of rituximab and group 2 (n = 15) received three or more infusions of rituximab at 1-week intervals. The number of infusions was determined by the choice of each patient. The endpoints of the study were time to disease control, partial remission (PR) and complete remission (CR). Results There was no significant difference in time to achieve PR between the two groups (147 vs. 135 days, P = 0·65). However, group 2 demonstrated better outcomes than group 1 in time to CR (443 vs. 149 days, P = 0·06) and relapse rate (0% vs. 67%, P < 0·01). Conclusions We conclude that three or more infusions of rituximab are more effective than two infusions for the treatment of pemphigus.
| Original language | English |
|---|---|
| Pages (from-to) | 646-651 |
| Number of pages | 6 |
| Journal | British Journal of Dermatology |
| Volume | 165 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2011 Sep 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Dermatology
Cite this
}
Clinical efficacy of different doses of rituximab in the treatment of pemphigus : A retrospective study of 27 patients. / Kim, J. H.; Kim, Y. H.; Kim, M. R.; Kim, S. C.
In: British Journal of Dermatology, Vol. 165, No. 3, 01.09.2011, p. 646-651.Research output: Contribution to journal › Article
TY - JOUR
T1 - Clinical efficacy of different doses of rituximab in the treatment of pemphigus
T2 - A retrospective study of 27 patients
AU - Kim, J. H.
AU - Kim, Y. H.
AU - Kim, M. R.
AU - Kim, S. C.
PY - 2011/9/1
Y1 - 2011/9/1
N2 - Summary Background The treatment of pemphigus is still challenging and some patients with pemphigus are unresponsive to conventional immunosuppressive treatments. Rituximab, a chimeric monoclonal anti-CD20 antibody, binds to the CD20 antigen on the surface of B cells and has been reported to be effective for the treatment of recalcitrant pemphigus. Objective To compare the efficacy of different doses of rituximab in patients with pemphigus who were unresponsive to conventional therapies. Methods Twenty-seven patients with pemphigus who received different doses of rituximab (375 mg m -2 per infusion weekly) were analysed retrospectively. We divided the patients into two groups: group 1 (n = 12) received two infusions of rituximab and group 2 (n = 15) received three or more infusions of rituximab at 1-week intervals. The number of infusions was determined by the choice of each patient. The endpoints of the study were time to disease control, partial remission (PR) and complete remission (CR). Results There was no significant difference in time to achieve PR between the two groups (147 vs. 135 days, P = 0·65). However, group 2 demonstrated better outcomes than group 1 in time to CR (443 vs. 149 days, P = 0·06) and relapse rate (0% vs. 67%, P < 0·01). Conclusions We conclude that three or more infusions of rituximab are more effective than two infusions for the treatment of pemphigus.
AB - Summary Background The treatment of pemphigus is still challenging and some patients with pemphigus are unresponsive to conventional immunosuppressive treatments. Rituximab, a chimeric monoclonal anti-CD20 antibody, binds to the CD20 antigen on the surface of B cells and has been reported to be effective for the treatment of recalcitrant pemphigus. Objective To compare the efficacy of different doses of rituximab in patients with pemphigus who were unresponsive to conventional therapies. Methods Twenty-seven patients with pemphigus who received different doses of rituximab (375 mg m -2 per infusion weekly) were analysed retrospectively. We divided the patients into two groups: group 1 (n = 12) received two infusions of rituximab and group 2 (n = 15) received three or more infusions of rituximab at 1-week intervals. The number of infusions was determined by the choice of each patient. The endpoints of the study were time to disease control, partial remission (PR) and complete remission (CR). Results There was no significant difference in time to achieve PR between the two groups (147 vs. 135 days, P = 0·65). However, group 2 demonstrated better outcomes than group 1 in time to CR (443 vs. 149 days, P = 0·06) and relapse rate (0% vs. 67%, P < 0·01). Conclusions We conclude that three or more infusions of rituximab are more effective than two infusions for the treatment of pemphigus.
UR - http://www.scopus.com/inward/record.url?scp=80052252494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052252494&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2133.2011.10411.x
DO - 10.1111/j.1365-2133.2011.10411.x
M3 - Article
C2 - 21574976
AN - SCOPUS:80052252494
VL - 165
SP - 646
EP - 651
JO - British Journal of Dermatology
JF - British Journal of Dermatology
SN - 0007-0963
IS - 3
ER -